CLOMIPHENE CITRATE

( ARTG ) INDICATIONS: Clomiphene citrate is indicated in the treatment of ovulatory failure in patients desiring pregnancy, whose partners have adequate sperm and who have potentially functional hypothalamic-hypophyseal ovarian systems and adequate endogenous oestrogens.‍‍‍‍‍‍​​​‍​​​​​​ Impediments to this goal must be excluded or adequately treated before beginning therapy. Administration of Clomiphene is indicated only in patients with demonstrated ovulatory dysfunction and in whom the following condition apply: 1. Demonstration of normal liver function 2. Physiological indications of normal or near normal endogenous oestrogen levels should be present (as estimated from vaginal smears, endometrial biopsy, assay of urinary or serum oestrogen or from bleeding in response to progesterone). Reduced oestrogen levels, while less favourable, do not prevent successful therapy. 3. Clomiphene citrate is not effective in patients with primary pituitary or ovarian failure. It cannot substitute for appropriate therapy of other disturbances leading to ovulatory dysfunction, e.g. diseases of the thyroid or adrenals. 4. Patients with abnormal uterine bleeding should be thoroughly evaluated prior to initiating Clomiphene therapy. It is most important that neoplastic lesions are detected.